GNLX Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -115587.5% compared to Genelux Corp.'s net margin of -31.03%. Genelux Corp.'s return on equity of -145.91% beat Agenus, Inc.'s return on equity of --.

Genelux Corp. has a consensus price target of $17.50, signalling upside risk potential of 580.93%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Genelux Corp. has higher upside potential than Agenus, Inc., analysts believe Genelux Corp. is more attractive than Agenus, Inc..

Genelux Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.

Genelux Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genelux Corp. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Genelux Corp. quarterly revenues are $8K, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Genelux Corp.'s net income of -$9.2M is higher than Agenus, Inc.'s net income of -$10.6M. Notably, Genelux Corp.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genelux Corp. is 11,970.70x versus 0.86x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arcutis Biotherapeutics, Inc. has a net margin of -115587.5% compared to Genelux Corp.'s net margin of 13.43%. Genelux Corp.'s return on equity of -145.91% beat Arcutis Biotherapeutics, Inc.'s return on equity of -10.26%.

Genelux Corp. has a consensus price target of $17.50, signalling upside risk potential of 580.93%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $34.75 which suggests that it could grow by 47.06%. Given that Genelux Corp. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Genelux Corp. is more attractive than Arcutis Biotherapeutics, Inc..

Genelux Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.813%.

Genelux Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genelux Corp. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Genelux Corp. quarterly revenues are $8K, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $129.5M. Genelux Corp.'s net income of -$9.2M is lower than Arcutis Biotherapeutics, Inc.'s net income of $17.4M. Notably, Genelux Corp.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genelux Corp. is 11,970.70x versus 8.03x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -115587.5% compared to Genelux Corp.'s net margin of 10.9%. Genelux Corp.'s return on equity of -145.91% beat CorMedix, Inc.'s return on equity of 67.96%.

Genelux Corp. has a consensus price target of $17.50, signalling upside risk potential of 580.93%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.57 which suggests that it could grow by 106.69%. Given that Genelux Corp. has higher upside potential than CorMedix, Inc., analysts believe Genelux Corp. is more attractive than CorMedix, Inc..

Genelux Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.406, suggesting its more volatile than the S&P 500 by 40.623%.

Genelux Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genelux Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Genelux Corp. quarterly revenues are $8K, which are smaller than CorMedix, Inc. quarterly revenues of $128.6M. Genelux Corp.'s net income of -$9.2M is lower than CorMedix, Inc.'s net income of $14M. Notably, Genelux Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genelux Corp. is 11,970.70x versus 1.83x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MBX Biosciences, Inc. has a net margin of -115587.5% compared to Genelux Corp.'s net margin of --. Genelux Corp.'s return on equity of -145.91% beat MBX Biosciences, Inc.'s return on equity of -29.61%.

Genelux Corp. has a consensus price target of $17.50, signalling upside risk potential of 580.93%. On the other hand MBX Biosciences, Inc. has an analysts' consensus of $62.55 which suggests that it could grow by 89.59%. Given that Genelux Corp. has higher upside potential than MBX Biosciences, Inc., analysts believe Genelux Corp. is more attractive than MBX Biosciences, Inc..

Genelux Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MBX Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genelux Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MBX Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genelux Corp. pays -- of its earnings as a dividend. MBX Biosciences, Inc. pays out -- of its earnings as a dividend.

Genelux Corp. quarterly revenues are $8K, which are larger than MBX Biosciences, Inc. quarterly revenues of --. Genelux Corp.'s net income of -$9.2M is higher than MBX Biosciences, Inc.'s net income of -$22.1M. Notably, Genelux Corp.'s price-to-earnings ratio is -- while MBX Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genelux Corp. is 11,970.70x versus -- for MBX Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.